MORRISVILLE,Trimeris cut its quarterly losses in the fourth quarter and for the year 2004 as sales of its HIV drug Fuzeon continue to grow, the company said Thursday.

Trimeris (Nasdaq: TRMS) said it lost $5.7 million in the fourth quarter, down from $8.3 million the previous quarter and slashed from a $15.1 million deficit in the same quarter of 2003.

Overall in 2004, Trimeris reduced its loss to $40.1 million from $65.7 million. In addition to Fuzeon sales, Trimeris said it helped cut losses through reduced research and development expenses.

Fuzeon sales hit $135.2 million in 2004, up from $36.5 million in 2003 when the drug was launched.

Trimeris produces and markets Fuzeon along with Roche.